Profile data is unavailable for this security.
About the company
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
- Revenue in USD (TTM)78.12m
- Net income in USD-153.22m
- Incorporated2013
- Employees265.00
- LocationEditas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
- Phone+1 (617) 401-9000
- Fax+1 (302) 655-5049
- Websitehttps://www.editasmedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrada Therapeutics Inc | 129.01m | -6.69m | 440.17m | 159.00 | -- | 1.81 | -- | 3.41 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Humacyte Inc | 0.00 | -110.78m | 440.61m | 183.00 | -- | 28.32 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Shattuck Labs Inc | 1.66m | -87.30m | 441.52m | 75.00 | -- | 3.04 | -- | 266.45 | -2.05 | -2.05 | 0.0389 | 3.06 | 0.0091 | -- | -- | 22,093.33 | -47.85 | -29.14 | -53.15 | -32.42 | -- | -- | -5,268.44 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Travere Therapeutics Inc | 145.24m | -376.33m | 445.24m | 380.00 | -- | 2.20 | -- | 3.07 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Fulcrum Therapeutics Inc | 2.81m | -97.34m | 449.03m | 76.00 | -- | 1.91 | -- | 160.08 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Theravance Biopharma Inc | 57.42m | -55.19m | 459.38m | 99.00 | -- | 2.14 | -- | 8.00 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Taysha Gene Therapies Inc | 15.45m | -111.57m | 460.07m | 52.00 | -- | 6.14 | -- | 29.78 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Editas Medicine Inc | 78.12m | -153.22m | 460.51m | 265.00 | -- | 1.31 | -- | 5.89 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Applied Therapeutics Inc | 9.99m | -119.76m | 466.96m | 25.00 | -- | -- | -- | 46.73 | -1.42 | -1.42 | 0.1288 | -0.202 | 0.2145 | -- | -- | 399,720.00 | -257.01 | -140.37 | -- | -240.93 | -- | -- | -1,198.47 | -4,476.42 | -- | -- | -- | -- | -- | -- | -45.15 | -- | -- | -- |
| C4 Therapeutics Inc | 20.76m | -132.49m | 470.60m | 145.00 | -- | 1.69 | -- | 22.67 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 474.12m | 130.00 | -- | 0.7187 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -30.82m | 474.32m | 30.00 | -- | 1.74 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Arbutus Biopharma Corp | 18.14m | -72.85m | 475.66m | 73.00 | -- | 4.23 | -- | 26.22 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 482.63m | 118.00 | -- | 4.47 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| SNDL Inc | 663.60m | -122.74m | 489.72m | 2.52k | -- | 0.5583 | -- | 0.738 | -0.4712 | -0.4839 | 2.56 | 3.37 | 0.5995 | 5.29 | 36.58 | 263,753.90 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
Data as of Apr 22 2024. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD
48.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 8.76m | 10.71% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 8.35m | 10.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 6.54m | 7.99% |
| Deep Track Capital LPas of 31 Dec 2023 | 5.47m | 6.69% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 2.39m | 2.92% |
| Pictet Asset Management SAas of 31 Dec 2023 | 1.98m | 2.42% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.90m | 2.32% |
| Millennium Management LLCas of 31 Dec 2023 | 1.59m | 1.94% |
| Two Sigma Investments LPas of 31 Dec 2023 | 1.46m | 1.78% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.19m | 1.45% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
